Rationale for combined therapies in severe-to-critical COVID-19 patients

An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause...

Descripción completa

Detalles Bibliográficos
Autores: Gonzaga, Aitor, Andreu, Etelvina, Hernández-Blasco, Luis M., Meseguer, Rut, Al-Akioui-Sanz, Karima, Soria-Juan, Bárbara, Sanjuan-Gimenez, Jose Carlos, Ferreras, Cristina, Tejedor, Juan Ramón, López-Lluch, Guillermo, Goterris, Rosa, Maciá, Loreto, Sempere-Ortells, Jose M., Hmadcha, Abdelkrim, Borobia, Alberto, Vicario, Jose L., Bonora, Ana, Aguilar-Gallardo, Cristobal, Poveda, Jose L., Arbona, Cristina, Alenda, Cristina, Tarín, Fabian, Marco, Francisco M., Merino, Esperanza, Jaime, Francisco, Ferreres, José, Figueira, Juan Carlos, Cañada-Illana, Carlos, Querol, Sergio, Guerreiro, Manuel, Eguizabal, Cristina, Martín-Quirós, Alejandro, Robles-Marhuenda, Ángel, Pérez-Martínez, Antonio, Solano, Carlos, Soria, Bernat
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Consejo Superior de Investigaciones Científicas (CSIC)
Repositorio:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/341905
Acceso en línea:http://hdl.handle.net/10261/341905
Access Level:acceso abierto
Palabra clave:COVID-19
Cytokine storm
Immunomodulation
Mesenchymal stromal cells
SARS-CoV-2
Advanced therapies
Descripción
Sumario:An unprecedented global social and economic impact as well as a significant number of fatalities have been brought on by the coronavirus disease 2019 (COVID-19), produced by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute SARS-CoV-2 infection can, in certain situations, cause immunological abnormalities, leading to an anomalous innate and adaptive immune response. While most patients only experience mild symptoms and recover without the need for mechanical ventilation, a substantial percentage of those who are affected develop severe respiratory illness, which can be fatal. The absence of effective therapies when disease progresses to a very severe condition coupled with the incomplete understanding of COVID-19’s pathogenesis triggers the need to develop innovative therapeutic approaches for patients at high risk of mortality. As a result, we investigate the potential contribution of promising combinatorial cell therapy to prevent death in critical patients.

Similares en LA Referencia